ESMO 2026: J&J delivers ‘immaculate’ early data for prostate cancer drug from Halda

JNJ-6143, which came from Johnson & Johnson’s $3 billion takeover of Halda Therapeutics in 2025, showed a 75% overall response rate in the Phase 1 readout.